Search Results

You are looking at 1 - 1 of 1 items for :

  • Growth Hormone in Endocrine Cancers x
  • Refine by access: All content x
Clear All
Xi Zhang Shenzhen Bay Laboratory, Shenzhen, P R China

Search for other papers by Xi Zhang in
Google Scholar
PubMed
Close
,
Vijay Pandey Tsinghua Berkeley Shenzhen Institute and Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, P R China

Search for other papers by Vijay Pandey in
Google Scholar
PubMed
Close
,
Vipul Bhardwaj Tsinghua Berkeley Shenzhen Institute and Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, P R China

Search for other papers by Vipul Bhardwaj in
Google Scholar
PubMed
Close
,
Tao Zhu Shenzhen Bay Laboratory, Shenzhen, P R China
Department of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, P R China
The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, P R China

Search for other papers by Tao Zhu in
Google Scholar
PubMed
Close
, and
Peter E Lobie Shenzhen Bay Laboratory, Shenzhen, P R China
Tsinghua Berkeley Shenzhen Institute and Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, P R China

Search for other papers by Peter E Lobie in
Google Scholar
PubMed
Close

phosphorylate multiple signaling pathways utilized by GH such as STAT3/STAT5 ( Wood et al. 1995 ), JNK ( Zhu et al. 1998 a ), p38 ( Zhu & Lobie 2000 ) and p44/42 MAP kinases ( Möller et al. 1992 ), PI3K/AKT and FAK ( Zhu et al. 1998 b ). GH has also

Restricted access